Stereotactic ablative radiotherapy (SABR) is a form of very precise radiotherapy that delivers high doses to tumors while sparing adjacent organs at risk. Recent data show that SABR is a low-toxic and highly effective local treatment for metastatic localizations in various organs, obtaining local control rates of approximately 80%. Experimental evidence also suggests that SABR may play an important therapeutic role in oligometastatic/oligorecurrent/oligoprogressive patients, a subset of cancer patients who are probably in an intermediate disease state between localized disease and widespread dissemination. There is a strong biological and clinical rationale in combining the high local control rates achievable with SABR with effective systemic therapies, and recent results of pilot studies indicate that SABR may have a potential impact on prognosis in this subgroup of patients, being 'curative' in around 20-25% of cases. This paper reviews and discusses basic concepts and clinical applications of SABR in oligometastatic patients.

New concepts and insights into the role of radiation therapy in extracranial metastatic disease

RICARDI, Umberto;FILIPPI, Andrea Riccardo;FRANCO, Pierfrancesco
2013-01-01

Abstract

Stereotactic ablative radiotherapy (SABR) is a form of very precise radiotherapy that delivers high doses to tumors while sparing adjacent organs at risk. Recent data show that SABR is a low-toxic and highly effective local treatment for metastatic localizations in various organs, obtaining local control rates of approximately 80%. Experimental evidence also suggests that SABR may play an important therapeutic role in oligometastatic/oligorecurrent/oligoprogressive patients, a subset of cancer patients who are probably in an intermediate disease state between localized disease and widespread dissemination. There is a strong biological and clinical rationale in combining the high local control rates achievable with SABR with effective systemic therapies, and recent results of pilot studies indicate that SABR may have a potential impact on prognosis in this subgroup of patients, being 'curative' in around 20-25% of cases. This paper reviews and discusses basic concepts and clinical applications of SABR in oligometastatic patients.
2013
13
10
1145
1155
Radiotherapy; Oligometastases; Stereotactic body radiation
Ricardi U; Filippi AR; Franco P
File in questo prodotto:
File Dimensione Formato  
SBRT oligomets review.pdf

Accesso riservato

Descrizione: pdf definitivo
Tipo di file: PDF EDITORIALE
Dimensione 272.92 kB
Formato Adobe PDF
272.92 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/138657
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact